|
|
- Patients with newly diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages are eligible:
|
|
|
|
|
|
|
|
|
- If study eligibility by staging is uncertain, consultation with Imaging and Radiation Oncology Core (IROC) Rhode Island (RI) may be obtained prior to study enrollment
|
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 or a serum creatinine based on age/gender as follows (performed within 14 days prior to enrollment):
|
- 2 to \< 6 years: male 0.8 mg/dL, female 0.8 mg/dL
|
- 6 to \< 10 years: male 1 mg/dL, female 1 mg/dL
|
- 10 to \< 13 years: male 1.2 mg/dL, female 1.2 mg/dL
|
- 13 to \< 16 years: male 1.5 mg/dL, female 1.4 mg/dL
|
- \>= 16 years: male 1.7 mg/dL, female 1.4 mg/dL
|
- Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age (performed within 14 days prior to enrollment)
|
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase \[AST\]) or serum glutamate pyruvate transaminase (SGPT) (alanine transaminase \[ALT\]) \< 2.5 x upper limit of normal (ULN) for age (performed within 14 days prior to enrollment)
|
- Shortening fraction of \>= 27% by echocardiogram, or ejection fraction of \>= 50% by radionuclide angiogram
|
- Forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) \> 60% by pulmonary function test (PFT), unless due to large mediastinal mass from Hodgkin lymphoma (HL)
|
- For children who are unable to cooperate for PFTs, the criteria are: no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry reading of \> 92% on room air
|
- All patients and/or their parents or legal guardians must sign a written informed consent
|
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
|